coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Igpc PCN, Liverpool (LAD) · Health Inequalities Profile

    PCN U02731 · NHS Cheshire and Merseyside Integrated Care Board · 8 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    59,116

    Registered population

    60.0% aged 18–64

    19.7%

    Aged 65+

    ICB 19.0% · England 17.9%

    9.4%

    Ethnic minority (non-White)

    3.9% Asian · England 9.6%

    43.9%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~25,830

    Core20 residents (est.)

    Resident basis; registered basis ~27,370 · see page 3

    10,544

    Hypertension register

    +6.24% in 3 yrs · England +5.60%

    736

    SMI register

    8.8% of Liverpool (LAD)'s

    2,024

    COPD register

    Reviews +14.50% in 3 yrs

    Forecast to 2030

    12,402

    Hypertension patients, 2030

    +1,858 on today

    83.5%

    QRISK ≥20% on statins, 2030

    +5.92pp over 3 yrs

    5.7%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    58.9%
    Asthma reviews trail despite high prescribing.

    Annual reviews fell -2.1% over 3 years to 58.9% (England 65.7%), leaving about 1,600 of 3,839 patients unreviewed while youth prescribing reaches 2,639 per.

    76.0%
    Pre-school boosters lag the 95.0% target.

    At age 5, 4-in-1 coverage is 76.0% (19 pp below the 95.0% target) and MMR2 is 78.4% (8.7 pp below MMR1 at 87.1%).

    69.9%
    Lipid therapy and blood pressure exceed England.

    QRISK ≥ 20% lipid therapy rose +9.3% over 3 years to 69.9% (England 63.6%), alongside 71.6% hypertension control (England 70.3%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older adults comprise 19.7% of list, exceeding Liverpool's 15.6% alongside 883 care beds

    IGPC PCN serves 59,116 registered patients. Patients aged 65+ account for 19.7% of the list (11,645 patients), compared with Liverpool (LAD) at 15.6%, NHS Cheshire and Merseyside Integrated Care Board at 19.0%, and England at 17.9%. Children aged 0-17 represent 20.3% (Liverpool (LAD) 19.8%; ICB 19.2%; England 19.6%), while 60.0% are aged 18-64 (Liverpool (LAD) 64.5%; ICB 61.9%; England 62.7%). Census resident data shows 90.6% White ethnicity (Liverpool (LAD) 84.0%; ICB 93.0%; England 81.1%), leaving a 9.4% non-White resident share; resident Census figures do not match registered patient ethnicity.

    Age profile

    0–1720.3%
    18–6460.0%
    65+19.7%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White90.6%
    Asian3.9%
    Mixed2.7%
    Other1.5%
    Black1.4%

    Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Liverpool LA)3,0352,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.6%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.7%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Liverpool LA)1,6521,0219552024/25
    Falls deaths, all ages, per 100,000 (Liverpool LA)27.518.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation reaches 43.9% PCN-wide but practice shares span 81.0 pp

    Across IGPC PCN, 43.9% of registered patients live in Core20 areas, compared with 54.9% in Liverpool (LAD), 31.9% in the ICB, and 21.0% in England. The weighted practice share is 46.3%, a 2.39 percentage points discrepancy against the PCN rate. Deprivation is sharply uneven: practice concentration spans 81.0 pp, with Rock Court Surgery at 81.0% and Rocky Lane Medical Centre at 0.0%. By volume, Old Swan Health Centre (6,979 patients) and Belle Vale Health Centre (6,579) carry the largest cohorts. Targeting must balance practice concentration against patient volume so large.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Rock Court81.0% · 4,467 patients
    Dovecot80.8% · 3,430 patients
    Belle Vale78.0% · 6,579 patients
    Old Swan77.7% · 6,979 patients
    Calvary51.5% · 1,975 patients
    West Derby19.0% · 2,343 patients
    Oak Vale12.5% · 1,597 patients
    Rocky Lane0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    736

    SMI register

    1.24% recorded prevalence

    382

    Learning disability register

    0.65% recorded prevalence

    22

    Care homes, 883 beds

    In the PCN catchment

    10.3%

    Provide unpaid care

    Liverpool (LAD), Census 2021

    The PCN records 736 patients on the severe mental illness register (1.2% versus Liverpool (LAD) 1.4%, ICB 1.1%, England 1.0%) and 382 on the learning disability register (0.7% versus 0.6% across Liverpool (LAD), ICB and England), alongside 883 beds across 22 catchment care homes. Crude recorded prevalence and care home bed capacity do not establish resident occupancy or which registered patients use these facilities.

    Severe mental illness: physical health checks

    Across 736 patients on the severe mental illness register (1.2%, England 1.0%), annual blood pressure checks reached 83.6% (England 83.4%) and BMI checks 82.9% (England 82.1%). Psychosis alcohol recording reached 86.4% (England 81.8%); broader physical checks were uncaptured.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    10,544

    Hypertension register

    +6.24%

    Register growth, 3 yrs

    Liverpool (LAD) +2.01% · England +5.60%

    +5.07pp

    BP control, under 80

    ≤140/90 · +3.26pp aged 80+

    +1,858

    More patients by 2030

    Forecast 12,402 (20.12%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 17.8% (10,544 patients), above Liverpool (LAD) at 14.0%, the ICB at 16.8% and England at 15.2%. Hypertensive patients treated to target reach 71.6%, exceeding Liverpool (LAD) at 69.8%, the ICB at 69.1% and England at 70.3%. However, annual heart failure reviews including functional capacity assessment fell 1.6% over three years (England +8.7%) to 73.8%, trailing England at 78.5% and the ICB at 76.4%, though above Liverpool (LAD) at 73.3%, across 752 registered patients (1.3% prevalence). While blood pressure control exceeds benchmarks, heart failure annual reviews trail England and ICB levels, indicating that prioritizing heart failure recall could address patients missing annual reviews.

    Lipids and statins

    In primary prevention, 69.9% of patients with QRISK ≥ 20% receive lipid-lowering therapy, above Liverpool (LAD) at 65.6%, the ICB at 63.2% and England at 63.6%, rising +9.3% over three years (England +6.2%). With coverage exceeding all benchmarks, prioritizing routine annual recall will help sustain high primary prevention therapy across the PCN.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026127,178£1.90£1.71£1.86£241,638
    Cardiovascular (all), 2025171,593£4.40£4.37£3.33£755,009

    In 2026, the PCN prescribed 127,178 lipid-modifying items at £1.90 per item (spend £241,638), above Liverpool (LAD) at £1.82, the ICB at £1.71 and England at £1.86, spending £5,087 more than at England's unit cost. Prescribing unit costs exceed comparators, so examining product mix across practices could clarify what drives this spend difference.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −2.15%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +3.34%

    Asthma prevalence, PCN 3-yr % change

    The PCN records 3,839 asthma patients (6.9% prevalence, England 6.6%) and 2,024 COPD patients (3.4%, England 1.9%). While COPD reviews reached 78.8% (England 76.4%), asthma reviews fell 2.1% over three years (England +4.4%) to 58.9% (England 65.7%; Liverpool (LAD) 64.3%), leaving about 1,600 patients unreviewed. Paediatric asthma prescribing reached 2,639 items per 1,000 aged 5-19 (England 1,488), while second-hand smoking recording lagged at 72.3% (England 78.8%). This pattern may reflect recall or maintenance gaps to verify locally.

    Cancer register and children's immunisation

    The cancer register records 2,723 patients (4.6% prevalence, England 3.8%). In Q1 2025/26, childhood immunisations trail national standards across 171 children at age 5. MMR2 coverage is 78.4% (below the 95.0% target by 16.6 pp; England 82.8%), trailing MMR1 (87.1%) by 8.7 pp. The 4-in-1 pre-school booster reaches 76.0% (below the 95.0% target by 19 pp; England 80.9%), indicating drop-off before school entry.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months82.6%

    England 91.0%

    6-in-1 complete primary course at 24 months91.2%

    England 92.2%

    MMR dose 1 at 24 months84.7%

    England 88.3%

    MMR dose 2 at age 578.4%

    England 82.8%

    4-in-1 pre-school booster at age 576.0%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2 (England 55.3%), 19.5 pp below the 75.0% national ambition by 2028, requiring about 2,640 extra early diagnoses annually. Staged cancers represented 72.8% of 18,522 registered tumours, with early diagnosis up 2.6 pp since 2013 ICB-wide. At PCN level, cervical screening coverage is 71.9% (England 66.8%), though Dovecot Health Centre achieves 64.3%, Old Swan Health Centre achieves 64.5%, and Calvary Health Centre achieves 66.4%. Prioritising screening recall in lower-coverage practices could help identify pre-cancerous changes earlier.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Liverpool University Hospitals NHS Foundation Trust, 62-day referral-to-treatment performance trailed the 85.0% standard by 11.7 pp, while NHS Cheshire and Merseyside Integrated Care Board was 8.8 pp below standard. On the 28-day faster diagnosis standard, the trust met the 75.0% threshold (0.5 pp above standard), while the ICB was 2.2 pp above. For the 31-day combined treatment standard, the trust was 5.5 pp below the 96.0% standard, compared with the ICB at 0.3 pp below. Provider waits on 62-day and 31-day pathways may delay treatment for referred patients, underscoring the importance of robust secondary-care tracking.

    Pathways within standard (%)LiverpoolMersey and West LancashireWirralCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)75.4772.3974.7177.2579.32
    31-day treatment (96%)90.5195.4692.5395.7192.50
    62-day referral to treatment (85%)73.2677.9677.6576.2371.16
    Diagnostic waits over 6 weeks (%)LiverpoolMersey and West LancashireWirralEngland
    MRI6.4214.041.5421.40
    CT0.7113.081.559.92
    Echocardiography12.5534.885.0728.48
    Colonoscopy33.1418.0432.8130.83
    Gastroscopy44.9918.1717.7329.02
    All 15 DM01 tests11.5021.175.0223.14
    Community services activityLiverpool residentsCheshire and Merseyside ICB
    Care contacts127,380541,280
    Referrals15,67597,150
    Patients with a contact24,970146,240

    Community services (residents of Liverpool), Jun 2026 (provisional). For Liverpool (LAD) residents, older adults aged 65+ accounted for 65.4% of community service contacts (83,300 of 127,380 contacts) in provisional Jun 2026 data. Community health services support older adults across the borough, though contacts reflect wider local authority activity rather than PCN-level oncology care.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    Clinical QOF achievement is consistently high, reaching 96.4% to 100.0% across practices against England's 97.1%. However, the vaccination and immunisation domain lags across all eight practices at 15.6% to 21.6% (England 55.2%), spanning 6.0 pp. Personalised care adjustments across all domains average 4.5% to 9.6% against England's 10.0%.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Calvary9451.586.0%63.9%96.0%
    Dovecot10780.874.9%72.9%92.6%
    Rock Court Surgery10581.050.9%70.6%87.6%
    Rocky Lane880.064.6%68.0%78.3%
    Old Swan9177.763.8%75.0%73.1%
    West Derby11019.032.5%64.5%70.8%
    Belle Vale9878.053.0%79.6%68.0%
    Oak Vale10312.535.3%64.6%63.2%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNLiverpool (LAD)AssetPCNLiverpool (LAD)
    Care homes (catchment)22 (883 beds)n/aSchools (catchment)112n/a
    Children's centres726Places of worship55240
    Libraries417Homelessness support (VCS)n/a1
    Primary schools (LA maintained)3091Primary academies420
    Special schools38

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review and prescribing recall

    Asthma reviews sit at 58.9% (England 65.7%; Liverpool (LAD) 64.3%) after falling 2.1% over 2023 to 2025 (England +4.4%), leaving about 1,600 of 3,839 registered patients unreviewed. For discussion: practices could run a standardised recall template combining annual review, inhaler check and second-hand smoke recording, offering after-school slots. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Heart failure review and capacity audit

    Heart failure reviews with functional capacity assessment sit at 73.8% (England 78.5%; ICB 76.4%; Liverpool (LAD) 73.3%) across 752 patients (1.3% prevalence), falling 1.6% over 2023 to 2025 (England +8.7%). For discussion: practices could audit the 752-patient register for overdue reviews and embed functional capacity prompts into multi-morbidity templates. Moderate effort to run.

    Option 3

    Pre-school booster and MMR2 catch-up recall

    In Q1 2025/26 (171 children aged 5), MMR2 is 78.4% (below the 95.0% target by 16.6 pp; England 82.8%), 8.7 pp below MMR1 (87.1%); 4-in-1 is 76.0% (below 95.0% by 19 pp). For discussion: practices could audit age-5 cohorts and proactively recall families missing MMR2 or 4-in-1 booster doses. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult service planning (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Two-track Core20 resource allocation (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Sustain severe mental illness checks (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Heart failure review audit (p5)Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs)—PCN
    Pre-school immunisation call and recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening uptake outreach (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Option 1 · Structured asthma review and prescribing recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · Heart failure review and capacity audit (p12)Heart failure register · Heart Failure: QOF prevalence · Patients with heart failure who had a review in the last 12 months including the assessment of functional capacity (denominator incl. PCAs)—PCN
    Option 3 · Pre-school booster and MMR2 catch-up recall (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15